Human aldo-keto reductases (AKRs) catalyze the NADPH-dependent reduction of carbonyl
groups to alcohols for conjugation reactions to proceed. They are implicated in resistance to …

The introduction of second-generation androgen receptor antagonists (SG-ARAs) has
greatly impacted the treatment of metastatic prostate cancer, providing tolerable and …

Aldo–keto reductase (AKR) 1C3 catalyzes the synthesis of active androgens that promote
the progression of prostate cancer. AKR1C3 also contributes to androgen-independent cell …

Aldo-keto reductase 1C3 (AKR1C3) is overexpressed in castration-resistant prostate cancer
where it acts to drive proliferation and aggressiveness by producing androgens. The …

As a crucial target which is overexpressed in a variety of cancers, aldo-keto reductase 1C3
(AKR1C3) confers chemotherapeutic resistance to many clinical agents. However, a limited …

Irinotecan (CPT11) is widely prescribed for treatment of various intractable cancers such as
advanced and metastatic colon cancer cells, but its continuous treatment promotes the …

Abstract Aldo-keto reductase 1C3 (AKR1C3) is a protein upregulated in prostate cancer,
hematological malignancies, and other cancers where it contributes to proliferation and …

Aims The recent approval of enzalutamide for metastatic castration-sensitive prostate cancer
underscores its growing clinical significance, raising concerns about emerging resistance …

Aldo-Keto Reductase Family 1 Member C3 (AKR1C3), also known as type 5 17β-
hydroxysteroid dehydrogenase (17β-HSD5) or prostaglandin F (PGF) synthase, functions as …

Malignant tumors have become a significant public health problem that severely threatens
human health. Drug-targeting therapy is essential for tumor therapy, along with surgery and …